Objectives: To evaluate the cost-utility of apixaban vs warfarin in patients with atrial fibrillation (AF) from the Peruvian Social Security (EsSalud) perspective. MethOds: A validated Markov decision model was adapted from EsSalud´s perspective. For efficacy and safety inputs, the model is based on data from the ARISTOTLE trial and clinical trials of warfarin therapy for AF. Resource utilization and costing of events were estimated using a reference hospital´s billing records and validated with local experts. Costs of procedures were obtained from official EsSalud tariffs. The costs of medications were obtained from SEACE. All costs are presented at 2014 nuevos soles. A discount rate of 3.5% was used for both costs and outcomes. A cohort of 1,000 patients was modeled using a lifetime horizon. Probabilistic sensitivity analysis (PSA) as well as univariate sensitivity analyses were performed. Results: The following outcomes were estimated: Total Ischemic Stroke (non-fatal mild, non-fatal moderate, non-fatal severe, fatal) apixaban: 147 vs. warfarin: 161. Total hemorrhagic stroke (non-fatal mild, non-fatal moderate, non-fatal severe, fatal) apixaban: 14 vs. warfarin 26. Other major bleeds (non-fatal GI bleeds, non-fatal non ICH or non GI related major bleeds, fatal): apixaban: 66 vs. warfarin: 85. Warfarin therapy resulted in a quality-adjusted life expectancy of 6.19 years at a cost of S/. 14,744. Treatment with apixaban led to a quality-adjusted life expectancy of 6.50 years at a cost of S/. 27,473. The costutility ratio was calculated at S/. 41,296 per QALY. Our findings were robust in univariate sensitivity analyses varying model inputs across plausible ranges. In Monte Carlo analysis, apixaban was cost-effective in 70% of simulations using the recommended threshold for WHO of 3 GDP per capita. cOnclusiOns: Apixaban is a cost-effective alternative relative to warfarin for secondary stroke prevention in patients with AF treated at EsSalud. Objectives: To assess the cost-effectiveness of monotherapy with a phosphodiesterase-5 (PDE-5) inhibitor, an endothelin receptor antagonist (ERA), or a prostanoid versus supportive care in patients with pulmonary arterial hypertension (PAH); and, to assess the cost-effectiveness of add-on combination therapy versus monotherapy PAH drugs. MethOds: A cost utility analysis based on a Markov model was designed to estimate costs and efficacy of both PAH monotherapy in treatment naïve patients and add-on therapies for treatment experienced patients. Separate analyses were conducted by PAH functional class (II, III). The primary outcome measure was the number of quality adjusted life years (QALYs) associated with treatment. Transition probabilities, based on the relative risk of improving and worsening in functional class with treatment versus placebo, were derived from a concurrent network meta-analysis. Utility values and costs were obtained from published data and clinical expert opinion. Extensive deterministic sensitivity analyses and probabilistic analysis were conducted. Results: For monotherapy versus supportive care, in the base case, sildenafil is considered the most cost-effective therapy for patients with PAH in functional class II and III. Tadalafil was also less costly and more effective than supportive care in functional class II and III; however, sildenafil was dominant over tadalafil. There were no studies comparing monotherapy with a PDE-5 inhibitor to add-on therapy. At a decision-maker's willingness to pay of less than ~$88,000 per QALY, neither add-on therapy with an ERA plus tadalafil nor add-on therapy with an ERA plus riociguat would be considered cost effective in patients with PAH in functional class II and III relative to an ERA alone. Despite the uncertainty in the clinical inputs, the probabilistic sensitivity analysis showed that apart from sildenafil and tadalafil, the other PAH therapies had negligible probability of being the most cost effective. cOnclusiOns: Sildenafil is considered the most cost-effective therapy for patients with PAH in functional class II and III. Objectives: To characterize Medicare patients with acute ischemic stroke (AIS) and describe healthcare resource utilization and associated direct costs during one-year pre-admission and follow-up period. MethOds: Medicare beneficiaries ages 65+ years with an incident AIS hospitalization in 2011 were identified from the 5% random Medicare Limited Data Set. Resources utilized and expenditures for hospitalizations, ICU stays, outpatient visits, rehabilitation, ER visits, and by types of services were measured during five phases: (1) pre-admission; (2) hospitalization to one-month; (3) 2-to 3-months; (4) 4-to 6-months; and (5) 7-months to 1-year. The differences in the mean annual costs pre-and post-AIS were compared. Results: We identified 6,697 AIS patients (age 79±8.0), 614 (9.2%) who were readmitted within 30 days. Resource utilization and costs in all categories were highest during the first 30 days and decreased progressively during follow up. The average cost per patient during hospitalization to one-month period was $16,219. The average cost was $4,588 at 2-to 3-months; $4,650 at 4-to 6-months; and $7,426 at 7-months to 1-year period. The average annual cost in the year following AIS was $32,882 per patient. The three highest annual average cost drivers were diagnostic/lab services ($27,263), followed by inpatient hospitalization ($19,226), Objectives: Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common cardiovascular disorder. Acute VTE is typically managed with a short course parenteral anticoagulation followed by 3-6 months vitamin-K antagonist. Novel oral anticoagulants do not require routine anticoagulation monitoring and dose adjustments, thus potentially providing an alternative treatment option. The cost-effectiveness of dabigatran etexilate vs. edoxaban was evaluated over six months of treatment in the UK care setting. MethOds: A life-time Markov model was used, evaluating costs and quality-adjusted life years (QALY) of recurrent VTE (rVTE) and VTE-related deaths, and most common adverse events during anticoagulation treatment, major or clinically relevant bleeds (MCRB). The efficacy and safety of dabigatran were based on the pooled RE-COVER treatment studies, and indirectly compared with results of The Hokusai Study for edoxaban. Utility estimates for rVTE, bleedings and longterm consequences of VTE were sourced from RE-COVER studies, and from the literature. Costs were analyzed from the perfective of the NHS and PSS. Results: Following index VTE, six months treatment with dabigatran etexilate was less costly and improved patients' quality of life when compared with six months edoxaban, assuming equal drug costs. Dabigatran projected more rVTEs overall, but less number of non-fatal PEs; dabigatran had less MCRB, hence the additional costs of rVTE were compensated by cost savings from avoidance of bleedings. Probabilistic sensitivity analyses showed 60% likelihood for dabigatran to be considered costeffective at a willingness-to-pay of £30,000. Evaluating the model for treatment in a Western-European population, with efficacy and safety from corresponding sub-groups of RE-COVER studies, and The Hokusai Study, dabigatran etexilate was projected to be less expensive and to improve patients' quality of life compared with edoxaban. cOnclusiOns: Dabigatran etexilate was projected less costly and safer than edoxaban when administered for six months following VTE. Objectives: The study objective was to investigate and compare the relative costs and effects of using azilsartan medoximil -chlorthalidone, a newly approved combination therapy in comparison to existing olmesartan medoximil -hydrochlorthiazide in treating mild to moderate essential hypertension, using the third party payer perspective and the risk of developing coronary heart disease (CHD) in 10 years. MethOds: A decision tree analysis was done using Tree Age Pro®. Cost evaluations included direct medical costs i.e. drug cost, cost of medical care (general physician and specialist visits) and cost to treat the adverse events, hospitalization and laboratory services over a time frame of one year. Cost values were obtained from the Red book 2010 and literature. Effectiveness was calculated by the reduction in SBP which was obtained, from various randomized controlled trials for these drugs. Incremental cost effectiveness ratio (ICER) was calculated. Monte Carlo simulation and probabilistic sensitivity analysis was done to further validate our findings. The risk of getting CHD in the next 10 years was calculated using Framingham risk score. Results: Outcomes favored azilsartan (8.51 mm Hg) with a total expected cost for treatment as $4759.46 to olmesartan (6.71 mm Hg) with a total cost as $4949.48. The ICER was 105.07. Patients on azilsartan have a 12% risk and patients on olmesartan have a 26% risk of developing CHD in the next 10 years. cOnclusiOns: This study showed that patients with mild/moderate essential hypertension on azilsartan have a lower risk of developing CHD when compared to those on olmesartan. Azilsartan is a cost effective therapy compared to olmesartan, in treating mild/moderate hypertension, from a third party payer perspective. Objectives: It is estimated that up to 400,000 persons in Mexico are hospitalized yearly for deep-vein thrombosis (DVT). DVT refers to the presence of a thrombus in the deep vein system. The main objective was to compare the treatment costs of tinzaparin, enoxaparin and nadroparin of patients with DVT from the institutional's view in Mexico. MethOds: We developed a cost-minimization model by using outcomes and resource utilization data from an indirect treatment comparison (no head-to-head trials compare these treatments) of patients with DVT. We found that recurrence and major bleeding was equally effective in all the LMWHs. Only direct medical costs were used, such as medications and adverse events; these were obtained from the portal shop by IMSS and also from their unitary costs. To prove the strength of the analysis, deterministic sensitivity analysis was performed; all the quantities are expressed in Mexican pesos (MXP) at 2014 Results: Tinzaparin sodium showed to be the less expensive LMWH for 10 days treatment of DVT; the savings resulted compared with nadroparin and enoxaparin were $670.44 hasta $1,111.40 respectively. Tinzaparin sodium reduced 28.48% of nadroparin total cost and 40.18% of enoxaparin total cost. ensitivity analysis did not change the conclusion that tinzaparium sodium is less expensive than nadroparin and enoxaparin (varying patient weight, duration of treatment and considering medication waste). cOnclusiOns: Tinzaparin sodium has the highest mean molecular weight (approximately 6,500 Da) of the commercially available LMWHs and is least dependent on renal clearance. In addition, tinzaparin sodium strategy is less expensive than the LMWHs strategy for the inpatient treatment of DVT in Mexico.
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